Minimally invasive valve repair reduces heart failure hospitalizations in patients with severe tricuspid regurgitation

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available medical therapy plus a minimally invasive procedure using a clip to repair the valve were 28% less likely to be hospitalized for recurrent heart failure than similar patients who were initially randomly assigned to medical therapy alone. The study was presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) on March 30 in Chicago. The study was simultaneously published online in Circulation.

Early IABP use no better than medication in cardiogenic shock due to heart failure

Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in patients who were critically ill with cardiogenic shock caused by heart failure did not improve 60-day survival or enable more patients to successfully transition to long-term treatment, according to featured clinical research presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) and simultaneously published in JACC. The trial was stopped early when an independent monitoring group of physicians concluded that the device offered patients no additional benefit.

Big Tobacco resorts to old tricks in campaign against UK’s historic Tobacco and Vapes Bill

The Tobacco Control Research Group (TCRG) at the University of Bath has published the first study examining tobacco and nicotine industry submissions on the 2023/24 Tobacco and Vapes Bill, introduced by the Conservative government. The Bill proposed banning tobacco sales to anyone born after 2009 and tightening regulations on nicotine products, including e-cigarettes. The Bill was later updated in 2024/25 by the current government.

Five-year outcomes similar for low-risk patients receiving transcatheter, surgical aortic valve replacement

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling stroke at five years compared with those whose valves were replaced through standard open heart surgery, based on new follow-up data from the Evolut Low Risk trial presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) on March 30 in Chicago.